Urinary excretion: Does it accurately reflect relative differences in bioavailability/systemic exposure when renal clearance is nonlinear?

Pharmaceutical Research

Volumn 21, Issue 5, 2004, Pages 781-784

  Thompson, Gary A ^a   Toothaker, Roger D ^a,b  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Bioavailability; Nonlinear renal clearance; Systemic exposure; Urinary excretion

Indexed keywords

ACCURACY; ARTICLE; BLOOD LEVEL; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; KIDNEY CLEARANCE; OSTEOPOROSIS; PRIORITY JOURNAL; URINARY EXCRETION;

ALGORITHMS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; KIDNEY; NONLINEAR DYNAMICS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; URINE;

EID: 3543029269     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAM.0000026428.48103.4f     Document Type: Article

References (29)

1. Food and Drug Administration. Bioavailability and bioequivalence requirements. Fed. Regist. 42:1624-1653 (1977).
2. W. J. Westlake. Use of statistical methods in evaluation of in vivo performance of dosage forms. J. Pharm. Sci. 62:1579-1589 (1973).
3. W. J. Westlake. Use of confidence intervals in analysis of comparative bioavailability trials. J. Pharm. Sci. 61:1340-1341 (1972).
4. E. Purich. Bioavailability/Bioequivalence Regulations: An FDA Perspective. In K. S. Albert (ed.), Drug Absorption and Disposition: Statistical Considerations, American Pharmaceutical Association Academy of Pharmaceutical Sciences, Washington, DC, 1980, pp. 115-137.
5. T. W. Dobbins and B. Thiyagarajan. A retrospective assessment of the 75/75 rule in bioequivalence. Stat. Med. 11:1333-1342 (1992).
6. D. J. Schuirmann. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15:657-680 (1987).
7. K. K. Midha, E. D. Ormsby, J. W. Hubbard, G. McKay, E. M. Hawes, L. Gavalas, and I. J. McGilveray. Logarithmic transformation in bioequivalence - application with 2 formulations of perphenazine. J. Pharm. Sci. 82:138-144 (1993).
8. W. W. Hauck and S. Anderson. Types of bioequivalence and related statistical considerations. Int. J. Clin. Pharm. Ther. Toxicol. 30:181-187 (1992).
9. L. B. Sheiner. Bioequivalence revisited. Stat. Med. 11:1777-1788 (1992).
10. J. G. Zhi. Initial slope technique to estimate first- and zero-order drug absorption rate constants. J. Pharm. Sci. 77:816-817 (1988).
11. H. Cheng, A. E. Staubus, and L. Shum. An area function method for estimating the apparent absorption rate constant. Pharm. Res. 5:57-60 (1988).
12. R. P. Basson, B. J. Cerimele, K. A. Desante, and D. C. Howey. Tmax: an unconfounded metric for rate of absorption in single dose bioequivalence studies. Pharm. Res. 13:324-328 (1996).
13. L. Endrenyi, S. Fritsch, and W. Yan. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int. J. Clin. Pharm. Ther. Toxicol. 29:394-399 (1991).
14. A. Rostamihodjegan, P. R. Jackson, and G. T. Tucker. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies - moving the "goalposts" or changing the "game". J. Pharm. Sci. 83:1554-1557 (1994).
15. M. L. Chen, V. Shah, R. Patnaik, W. Adams, A. Hussain, D. Conner, M. Mehta, H. Malinowski, J. Lazor, S. M. Huang, D. Hare, L. Lesko, D. Sporn, and R. Williams. Bioavailability and bioequivalence: An FDA regulatory overview. Pharm. Res. 18: 1645-1650 (2001).
16. Food and Drug Administration. Bioavailability and bioequivalence studies for orally administered drug product: general considerations. Available at: www.fda.gov/cder/guidance/index.htm (2003)
17. Food and Drug Administration. Exposure-response relationships - study design, data analysis, and regulatory applications. Available at: www.fda.gov/cder/guidance/index.htm (2003)
18. M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, Inc., New York, 1982.
19. P. L. Bonate, K. Reith, and S. Weir. Drug interactions at the renal level: Implications for drug development. Clin. Pharmacokinet. 34:375-404 (1998).
20. J. V. S. Gobburu and P. J. Marroum. Utilisation of pharmacokinetic- pharmacodynamic modelling and simulation in regulatory decision-making. Clin. Pharmacokinet. 40:883-892 (2001).
21. B. J. Gertz, S. H. Holland, W. F. Kline, B. K. Matuszewski, A. Freeman, H. Quan, K. C. Lasseter, J. C. Mucklow, and A. G. Porras. Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther. 58:288-298 (1995).
22. A. G. Porras, S. D. Holland, and B. J. Gertz. Pharmacokinetics of alendronate. Clin. Pharmacokinet. 36:315-328 (1999).
23. D. Y. Mitchell, M. A. Heise, K. A. Pallone, M. E. Clay, J. D. Nesbitt, D. A. Russell, and C. W. Melson. The effect of dosing regimen on the pharmacokinetics of risedronate. Brit. J. Clin. Pharmacol. 48:536-542 (1999).
24. D. Y. Mitchell, R. A. Eusebio, N. A. Sacco-Gibson, K. A. Pallone, S. C. Kelly, J. D. Nesbitt, C. P. Brezovic, G. A. Thompson, and J. H. Powell. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J. Clin. Pharmacol. 40:258-265 (2000).
25. G. A. Thompson, J. H. Powell, and S. Mallikaarjun. Bisphosphonate renal clearance: Assessment of linearity. Pharm. Res. 14:S-510 (1997).
26. K. Besseghir and F. Roch-Ramel. Renal excretion of drugs and other xenobiotics. Renal Physiol. 10:221-241 (1987).
27. W. Weber, M. Nitz, and M. Looby. Nonlinear kinetics of the thiamine cation in humans: Saturation of nonrenal clearance and tubular reabsorption. J. Pharmacokinet. Biopharm. 18:501-523 (1990).
28. W. Weber, S. Toussaint, M. Looby, M. Nitz, and H. Kewitz. System analysis in multiple dose kinetics: Evidence for saturable tubular reabsorption of the organic cation N1-methylnicotinamide in humans. J. Pharmacokinet. Biopharm. 19:553-574 (1990).
29. C. A. M. Van Ginneken and F. G. M. Russel. Saturable pharmacokinetics in the renal excretion of drugs. Clin. Pharmacokinet. 16:38-54 (1989).